ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » Measures and Measurement of Healthcare Quality Poster II

Date: Tuesday, November 7, 2017

Time: 9:00AM-11:00AM

Meeting: 2017 ACR/ARHP Annual Meeting

9:00AM-11:00AM
Abstract Number: 2043
Adherence to American College of Rheumatology Guidelines for Prevention of Glucocorticoid-Induced Osteoporosis in Patients with Polymyalgia Rheumatica
9:00AM-11:00AM
Abstract Number: 2035
Clinical Audit of Hydroxychloroquine Dosing and Toxicity Screening in Patients with Inflammatory Arthritis and Connective Tissue Diseases
9:00AM-11:00AM
Abstract Number: 2028
Compliance with Pneumococcal Vaccination in Rheumatic Disease Patients on Immunosuppressive Medications
9:00AM-11:00AM
Abstract Number: 2047
Development and Implementation of a “Data-in-Once” Model for a Pediatric Rheumatology Learning Health System
9:00AM-11:00AM
Abstract Number: 2046
Development and Validation of a Rheumatologist Satisfaction with Practice Scale –“ the Rheumatologist Satisfaction Scale” (RSS)
9:00AM-11:00AM
Abstract Number: 2032
Evaluation of RA Outcome Measures between Users and Non-Users of the Patient Portal
9:00AM-11:00AM
Abstract Number: 2037
HLA-B27 Testing in Patients >= 45 Years of Age and Subsequent Diagnosis of Late Onset Spondyloarthritis
9:00AM-11:00AM
Abstract Number: 2029
Improved Provider Awareness and Delivery of Zoster Vaccination in Patients with Rheumatoid Arthritis Contemplating Biologic Therapy: Need to Target Eligible Patients Prescribed for Vaccination Post-Clinic
9:00AM-11:00AM
Abstract Number: 2040
Improving Quality of Care for Rheumatoid Arthritis Patients in an Underserved Area
9:00AM-11:00AM
Abstract Number: 2033
Low Health Literacy Does Not Impact Adherence to Hydroxychloroquine in Patients with Systemic Lupus
9:00AM-11:00AM
Abstract Number: 2034
New Guidelines on Hydroxychloroquine Dosage – Where Are We?
9:00AM-11:00AM
Abstract Number: 2031
Online Viewing of Labs in RA Patients Is Not Associated with Clinically Significant Change in ESR over 18 Months Compared to Non-Viewers
9:00AM-11:00AM
Abstract Number: 2030
Patient Motivation in Inflammatory Arthritis: The Use of Ultrasound-Guided Patient Education to Endorse Medication Adherence and Facilitate Cost-Effective Targeted Management
9:00AM-11:00AM
Abstract Number: 2026
Pneumococcal Vaccination Rates: Improving Safety in Immunocompromised Patients
9:00AM-11:00AM
Abstract Number: 2041
Practice Improvement Utilizing Six Sigma and Health Informatics in an Academic Setting
9:00AM-11:00AM
Abstract Number: 2027
Pre-Visit Planning Improves Pneumococcal Vaccination in Patients with Childhood-Onset Systemic Lupus Erythematosus
9:00AM-11:00AM
Abstract Number: 2045
Prophylaxis of Ischemic Disease in Giant Cell Arteritis Patients: An Application of a “Big Data” Tracking Tool in the Electronic Health Record in an University-Based Medical Center
9:00AM-11:00AM
Abstract Number: 2038
Radiological Changes Measured By MRI and High-Resolution Peripheral Quantitative Computed Tomography (HR-pQCT) Show Correlation with Michigan Hand Outcome Questionnaire (MHQ) in Rheumatoid Arthritis Patients
9:00AM-11:00AM
Abstract Number: 2042
Referral Criteria to an Early Arthritis Clinic: Poor Agreement between Referring Physicians and Rheumatologists
9:00AM-11:00AM
Abstract Number: 2036
Rheumatologists’ Compliance with Screening for Viral Hepatitis B and C Prior to Initiation of Methotrexate Treatment Needs Quality Improvement
9:00AM-11:00AM
Abstract Number: 2044
Secondary Prevention of Cardiovascular Disease Is Incomplete in a Systemic Lupus Erythematosus Population-Based Cohort
9:00AM-11:00AM
Abstract Number: 2048
the Impact of Diagnostic Misregistration of Rheumatoid Arthritis on the Establishment of a Value Based Healthcare System
9:00AM-11:00AM
Abstract Number: 2039
Validity of the Wpai-SHP in Psoriatic Arthritis and Estimation of the Minimally Important Difference

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology